To better understand the clinical benefits of CDK4/6 inhibitors in patients with advanced breast cancer who are HR+ and HER2-, we conducted a meta-analysis comparing pooled data on the use of CDK4/6 inhibitors versus placebo from the most recent reports. The gene discussed is CDK4; the disease is breast carcinoma.